iiinova — where your digital self keeps evolving

GSK @gsk.com · 14/09/2026

#News for #investors and #media: Today, we announced new positive data at #WCLC26 representing encouraging news for people living with ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4cJsjhu

011

GSK @gsk.com · 13/09/2026

#News for #investors and #media: Today, our licensor Hansoh Pharma presented positive data at #WCLC26 from a pivotal trial of an investigational antibody-drug conjugate in our pipeline. Learn more: gsk.to/4xrKoZ1

002

GSK @gsk.com · 10/09/2026

#News for #Investors and #Media: Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved a new prefilled syringe presentation of one of our vaccines. Learn more: gsk.to/4xMvugV

000

GSK @gsk.com · 09/09/2026

The data we’ve shared at #ERSCongress underscores how much more we can achieve for respiratory patients when science and partnership come together. #ERSCongress

010

GSK @gsk.com · 05/09/2026

We believe the future of respiratory care needs to be as diverse as the patients living with respiratory disease, supporting real-world use with longer-acting solutions that aim to offer greater choice and improve adherence.

030

GSK @gsk.com · 01/09/2026

#News for #Investors and #Media: Today we announced Phase II data for a seasonal flu vaccine candidate at #OPTIONSXIII. Learn more: gsk.to/4iDDU5g

000

GSK @gsk.com · 24/08/2026

#News for #investors & #media: Japan has become the first country to approve a new therapy for people living with chronic hepatitis B (CHB). This approval reflects continued commitment to progress in liver disease research. Learn more: gsk.to/45Goq9d

010

GSK @gsk.com · 24/08/2026

#News for #Investors and #Media: Today we announced that the US FDA accepted the application for one of our immuno-oncology therapies for priority review. Learn more: gsk.to/3U5ph0D

000

GSK @gsk.com · 29/07/2026

Yesterday we announced we will be establishing a new flagship R&D centre on the Cambridge Biomedical Campus. Learn more gsk.to/4be2p4M

020

GSK @gsk.com · 29/07/2026

#News for #Investors and #Media: At #AIDS2026 we’re presenting new clinical and real-world insights from across our long-acting portfolio and pipeline for #HIV treatment and prevention, through our specialist HIV company, ViiV Healthcare. 👉 Find out more: gsk.to/44YUip5

020

GSK @gsk.com · 28/07/2026

Our global survey findings reveal ongoing misunderstandings about chronic hepatitis B (CHB), including gaps in awareness about prevention and its link to liver cancer. On #WorldHepatitisDay, learn more about the realities of living with CHB: gsk.to/4pG6Pai

040

GSK @gsk.com · 28/07/2026

Today we’re announcing a £400 million investment in UK life sciences including plans to establish a new flagship R&D centre in Cambridge. The new site on the city’s Biomedical Campus, one of the world’s leading life sciences ecosystems, will be a catalyst to fuel collaboration and accelerate GSK R&D

020

GSK @gsk.com · 28/07/2026

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q2 core performance, continued momentum and plans to accelerate our R&D, including a new flagship R&D centre in Cambridge. Find out more: gsk.to/45qwVVv #Q2Results $GSK

111

GSK @gsk.com · 28/07/2026

#News for #investors and #media: Today our licensor Hansoh Pharma announced another positive pivotal dataset on an investigational antibody-drug conjugate in our oncology pipeline. Learn more: gsk.to/45w7cLi

000

GSK @gsk.com · 27/07/2026

#News for #Investors and #Media: We are announcing new data from the first randomised head-to-head study comparing daily oral 2-drug regimen vs 3-drug regimen in treatment-naïve adults at #AIDS2026. Find out more in the press release gsk.to/44QBFUg

000

GSK @gsk.com · 22/07/2026

#News for #Investors and #Media: Today we announced that the US Food and Drug Administration (FDA) granted approval for one our therapies to treat ROS1-positive non-small cell lung cancer. Learn more: gsk.to/4yButJ9

000

GSK @gsk.com · 21/07/2026

#News for #Investors and #Media: We’ll be at #AIDS2026 with ViiV Healthcare, our specialist HIV company, presenting research and insights from our innovative portfolio and integrase strand transfer inhibitor (INSTI)-powered pipeline. 👉 Find out more in the press release: gsk.to/4fdROcs

001

GSK @gsk.com · 20/07/2026

#News for #Media and #Investors: Today we announced that the EMA has accepted our submission to update the label of one of our meningococcal vaccines. If approved, this could enable a 1-dose booster for certain individuals. Learn more: gsk.to/4wf6det

000

GSK @gsk.com · 16/07/2026

#News for #Investors and #Media: Today marks another step forward for a GSK-developed vaccine candidate. This significant step reinforces our commitment to partnerships that help improve global public health. Learn more: gsk.to/3T0EVd6

000

GSK @gsk.com · 15/07/2026

#News for #investors and #media: Today we announced the completion of our acquisition of clinical-stage precision oncology company Nuvalent, Inc., bringing in multiple lung cancer assets to our existing oncology portfolio. Find out more: gsk.to/44vsRTI

000

GSK @gsk.com · 13/07/2026

#News for #Media and #Investors: We’re excited to announce interim positive headline results from one of our clinical trial evaluating our immuno-oncology therapies. More here: gsk.to/4w59dKg

010

GSK @gsk.com · 10/07/2026

#News for #Investors and #Media: Today, our licensor Hansoh Pharma announced pivotal data on an investigational antibody-drug conjugate in our oncology pipeline for the treatment cancers with high unmet needs. Learn more: gsk.to/4vpmVGN

000

GSK @gsk.com · 17/06/2026

#News for #Media and #Investors: The FDA has approved our oral anti-infective for complicated urinary tract infections (cUTIs). With three million cUTIs treated annually in the US, this approval reflects our commitment to innovation in anti-infectives. Learn more: gsk.to/44gOOFG

000

GSK @gsk.com · 12/06/2026

Our new website, YourCancerOurChallenge.com, provides education and resources to support patients impacted by ovarian and endometrial cancers, myelofibrosis and multiple myeloma, from diagnosis and beyond. Discover the patient-driven tools we’re bringing to the community: bit.ly/4vMHjCl

000

GSK @gsk.com · 12/06/2026

#News for #Investors and #Media: Today we announced that the US FDA and the EMA have granted regulatory designations for one of our therapies for the treatment of VEXAS syndrome. Learn more: gsk.to/444M6Da

000

GSK @gsk.com · 10/06/2026

A child’s first steps. Dinner with old friends. What moments – big or small – matter to you? 🧡 Driven by our deep understanding of the root causes of disease, we’re accelerating our R&D in areas where we can make the most meaningful difference to patients. 🔗 gsk.to/3PPoNtO

061

GSK @gsk.com · 09/06/2026

We’ve announced an agreement to acquire Nuvalent, Inc. Find out more: gsk.to/4vC0wGv

000

GSK @gsk.com · 02/06/2026

That's a wrap on #ASCO26! We're proud of our oncology progress. Our existing portfolio is focused on creating a positive impact and our R&D pipeline aims to bring more innovative medicines to patients. Watch our oncology leaders, Hesham Abdullah and Ali Çimen, reflect on an inspiring weekend ⤵️

000

GSK @gsk.com · 31/05/2026

Have you heard of antibody-drug conjugates (ADCs)? These innovative therapies are becoming a promising option for more targeted cancer treatment, and our researchers are at the forefront of advancing their potential. Curious to learn more? 🔗 Hear from our leading experts: bit.ly/42ZvUTd

000

GSK @gsk.com · 28/05/2026

#News for #investors & #media: Today at #EASLCongress, we’re presenting results from a phase III trial in chronic hepatitis B, a disease affecting approximately 240 million people globally. Learn more: gsk.to/3S77yoc

021

GSK @gsk.com · 26/05/2026

#News for #investors and #media: We're excited to be at #ASCO26 and #EHA2026, where we will share data on how we're delivering a meaningful impact for cancer patients today while innovating for tomorrow. Learn more: gsk.to/49hUlis

010

GSK @gsk.com · 18/05/2026

#News for #Investors and #Media: Today, we are announcing that one of our vaccines has been approved for an expanded population by the Japanese Ministry of Health, Labour and Welfare (MHLW). Learn more: gsk.to/4eSI47M

000

GSK @gsk.com · 06/05/2026

At our recent virtual event with Washington Post Live Hesham Abdullah, Global Head of Oncology R&D at GSK and Peter Lee, President of Microsoft Science, shared how cutting-edge technology is fuelling the mission to improve outcomes for people living with cancer – and to do so more quickly.

100

GSK @gsk.com · 06/05/2026

#News for #investors and #media: At #ATS2026, we’ll be presenting data across 33 abstracts to highlight our research as we work to redefine respiratory care. gsk.to/4nmDlx9

000

GSK @gsk.com · 29/04/2026

News for #Investors and #Media Watch our CEO Luke Miels as he shares our strong Q1 performance and start to 2026 ⤵️ Find out more: gsk.to/4ePgo3m $GSK #earnings

110

GSK @gsk.com · 28/04/2026

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review by US FDA. Learn more: gsk.to/3Qz28Sq

021

GSK @gsk.com · 27/04/2026

#News for #investors and #media: Today we announced that our investigational liver therapy received US FDA Breakthrough Therapy and EMA Priority Medicine (PRIME) regulatory designations for metabolic dysfunction-associated steatohepatitis (MASH). Find out more: gsk.to/3Qp3P4V

010

GSK @gsk.com · 23/04/2026

Symptoms of CRSwNP, like nasal obstruction, facial pain and sleep disturbances, can greatly impact a person’s quality of life. Today, on #WorldCRSwNPDay, we’re reinforcing our commitment to improving patient outcomes. See how: gsk.to/4twp830

000

GSK @gsk.com · 20/04/2026

#News for #Investors and #Media China’s National Medical Products Administration (NMPA) has approved our therapy to treat an incurable and challenging blood cancer. For more information, visit: gsk.to/3QPIamj

000

GSK @gsk.com · 15/04/2026

#News for #investors and #media: Today we announced the completion of our acquisition of 35Pharma Inc., adding to our Respiratory, Immunology & Inflammation pipeline. Find out more: gsk.to/4ccpQw3

011

GSK @gsk.com · 12/04/2026

#News for #Investors and #Media: Today at #SGO2026, we’re presenting new data on an investigational antibody-drug conjugate from our oncology pipeline. Learn more: gsk.to/3Q00jh7

000

GSK @gsk.com · 10/04/2026

We're at #SGO26! With an innovative pipeline, we’re building on our strong foundations in oncology research to improve how people live with cancer 🧡 Join us as we share more about our vision for transforming cancer care. 🔗 Learn more: bit.ly/4dz0866

100

GSK @gsk.com · 10/04/2026

Antibody-drug conjugates (ADCs) - what exactly are they? ➡️ Swipe to find out how this innovation technology works to target cancer cells. 🔗 And dive deeper into the world of ADCs in our latest Behind the Science article: bit.ly/41kHkjL

Antibody-drug conjugates (ADCs) seek out cancer cells within the body.

ADC binds to the antigen on the cancerous cell. The ADC is absorbed into the cancerous cell.

Enzymes inside the cell break down the ADC linker and release the payload/drug to kill the cancerous cell.

010

GSK @gsk.com · 08/04/2026

#News for #Media and #Investors: China's National Medical Products Administration (NMPA) has approved our new therapy for people living with chronic rhinosinusitis with nasal polyps (CRSwNP). For more information, visit: bit.ly/43sHkQ0

000

GSK @gsk.com · 02/04/2026

The UK-US deal on pharmaceuticals is now finalised, an important step for UK life sciences. Read our short statement ⤵️

000

GSK @gsk.com · 30/03/2026

#News for #investors and #media: Today we are announcing that our potential treatment for chronic hepatitis B has been accepted for regulatory review in China. Learn more: gsk.to/4uZos7p

010

GSK @gsk.com · 30/03/2026

#News for #Media and #Investors: China’s National Medical Products Administration (NMPA) has approved our new therapy for the treatment of severe asthma. For more information, visit: gsk.to/47tXAlQ

000

GSK @gsk.com · 27/03/2026

#News for #investors and #media: Today we are announcing that our potential first-in-class treatment for chronic hepatitis B has been accepted for regulatory review by the EMA. Learn more: gsk.to/489nuvm

000

GSK @gsk.com · 23/03/2026

#News for #Investors and #Media: Today we announced that Japan’s Ministry of Health, Labour and Welfare has granted Orphan Drug Designation to an investigational antibody-drug conjugate in our oncology pipeline. Learn more: gsk.to/4sZtdvP

000

GSK @gsk.com · 19/03/2026

#News for #investors and #media: Today, we are announcing that one of our liver medicines has been approved by the US Food and Drug Administration (FDA). Find out more: gsk.to/4bHlfke

000